Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population
Author: Hein, N.
Cameron, D.
Hannan, K.
Nguyen, N.
Fong, C.
Sornkom, J.
Wall, M.
Pavy, M.
Cullinane, C.
Diesch, J.
Devlin, J.
George, A.
Sanij, E.
Quin, J.
Poortinga, G.
Verbrugge, I.
Baker, A.
Drygin, D.
Harrison, S.
Rozario, J.
et al.
Citation: Blood, 2017; 129(21):2882-2895
Publisher: American Society of Hematology
Issue Date: 2017
ISSN: 0006-4971
Statement of
Nadine Hein, Donald P. Cameron, Katherine M. Hannan, Nhu-Y N. Nguyen, Chun Yew Fong, Jirawas Sornkom, Meaghan Wall, Megan Pavy, Carleen Cullinane, Jeannine Diesch, Jennifer R. Devlin, Amee J. George, Elaine Sanij, Jaclyn Quin, Gretchen Poortinga, Inge Verbrugge, Adele Baker, Denis Drygin, Simon J. Harrison, James D. Rozario, Jason A. Powell, Stuart M. Pitson, Johannes Zuber, Ricky W. Johnstone, Mark A. Dawson, Mark A. Guthridge, Andrew Wei, Grant A. McArthur, Richard B. Pearson and Ross D. Hannan
Abstract: Despite the development of novel drugs, the prospects for many patients with acute myeloid leukemia (AML) remain dismal. This study reveals that the selective inhibitor of RNA polymerase I (Pol I) transcription, CX-5461, effectively treats aggressive AML, including mixed-lineage leukemia-driven AML, and outperforms standard chemotherapies. In addition to the previously characterized mechanism of action of CX-5461 (ie, the induction of p53-dependent apoptotic cell death), the inhibition of Pol I transcription also demonstrates potent efficacy in p53null AML in vivo. This significant survival advantage in both p53WT and p53null leukemic mice treated with CX-5461 is associated with activation of the checkpoint kinases 1/2, an aberrant G2/M cell-cycle progression and induction of myeloid differentiation of the leukemic blasts. The ability to target the leukemic-initiating cell population is thought to be essential for lasting therapeutic benefit. Most strikingly, the acute inhibition of Pol I transcription reduces both the leukemic granulocyte-macrophage progenitor and leukemia-initiating cell (LIC) populations, and suppresses their clonogenic capacity. This suggests that dysregulated Pol I transcription is essential for the maintenance of their leukemia-initiating potential. Together, these findings demonstrate the therapeutic utility of this new class of inhibitors to treat highly aggressive AML by targeting LICs.
Keywords: Cell Line, Tumor; Animals; Mice, Inbred NOD; Humans; Mice; Mice, Mutant Strains; Naphthyridines; Pol1 Transcription Initiation Complex Proteins; Cell Division; G2 Phase; Transcription, Genetic; Tumor Suppressor Protein p53; Benzothiazoles; Neoplastic Stem Cells; Leukemia, Myeloid, Acute; Checkpoint Kinase 2; Checkpoint Kinase 1
Rights: © 2017 by The American Society of Hematology
RMID: 0030066483
DOI: 10.1182/blood-2016-05-718171
Grant ID:
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.